KW-6356


Selective non-xanthine adenosine A2A receptor antagonist and inverse agonist

A second-generation, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin as a successor to istradefylline for the treatment of Parkinson’s disease, distinguished by insurmountable antagonism, inverse agonist activity, and approximately 100-fold greater receptor affinity than the first-generation A2A antagonist class.

Abstract

KW-6356 (sipagladenant; CAS 858979-50-7) is a selective, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin) as a next-generation successor to istradefylline (NOURIANZ/NOURIAST) for the treatment of motor and non-motor symptoms of Parkinson’s disease. The compound exhibits approximately 100-fold greater binding affinity for the human adenosine A2A receptor than istradefylline (pKi 9.93 versus approximately 7.9), with a Kd of 0.13 nM and a Ki of 0.12 nM at the human A2A receptor, and demonstrates greater than 100-fold selectivity over the A1, A2B, and A3 adenosine receptor subtypes [1]. In contrast to istradefylline, which acts as a surmountable antagonist, KW-6356 exhibits two pharmacologically distinct properties: insurmountable antagonism (the capacity to suppress receptor signaling in a manner that cannot be fully overcome by increasing agonist concentration) and inverse agonism (the capacity to reduce constitutive, agonist-independent receptor activity below basal levels). X-ray crystallography of the KW-6356-bound human A2A receptor at 2.30 angstrom resolution (PDB: 8GNE) has revealed that interactions with His250 (position 6.52) and Trp246 (position 6.48) are essential for the inverse agonist activity, while deep orthosteric pocket contacts and stabilization of the extracellular loop conformation contribute to the insurmountable antagonism [1].

The clinical development program evaluated KW-6356 in two pivotal Phase 2 studies in Japanese Parkinson’s disease populations.

Population pharmacokinetic modeling identified food status, baseline serum albumin, and baseline body weight as covariates, but none had clinically meaningful impact on KW-6356 or M6 exposure [8]. The most common adverse events in the Phase 2a monotherapy trial were constipation (7.3 percent at 3 mg, 6.9 percent at 6 mg) and nasopharyngitis (7.3 percent at 3 mg, 8.6 percent at 6 mg) [2].

Despite positive proof-of-concept results across both monotherapy and adjunct-to-levodopa settings, Kyowa Kirin announced discontinuation of the KW-6356 development program in July 2022, citing evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry rather than efficacy or safety concerns [9]. The discontinuation followed Lundbeck’s earlier decision to return ex-Asia development rights to Kyowa Kirin. No Phase 3 trials were initiated. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph